Equillium Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing treatments for severe autoimmune and inflammatory disorders. The company has no approved products and generates no product revenue, operating entirely on capital raised through financing activities. Equillium was incorporated in Delaware in March 2017 as Attenuate Biopharmaceuticals, Inc. and renamed in May 2017, with principal offices in La Jolla, California. The company operates through three wholly-owned subsidiaries: Bioniz Therapeutics, Inc., Ariagen, Inc., and Equillium Australia Pty LTD, reflecting assets acquired through merger and stock purchase agreements. Cash requirements are funded through operating leases and cancelable purchase orders with third-party service providers who handle manufacturing, clinical data management, biostatistics, and safety reporting. Contingent milestone and royalty payment obligations exist under the Bioniz merger agreement, the Ariagen stock purchase agreement, and potential future license agreements, none of which were triggered as of the 10-K filed March 25, 2026.

Revenue model

No product revenue disclosed in the filing excerpts. The company is pre-revenue and funds operations through financing activities. Potential future revenue streams include product sales upon regulatory approval and royalties or milestone payments under license agreements not yet executed as of the filing date.

Products and services

The filing excerpts do not specify named drug candidates or clinical programs by product name. The company holds patents with terms up to 20 years from non-provisional filing dates, with potential U.S. patent term extensions under the Hatch-Waxman Act of up to five years for FDA-approved drugs. Drug manufacturing and clinical operations are outsourced to third-party service providers.

Customers and end markets

The filing excerpts do not identify specific customers, patient populations, or commercial end markets. The company targets severe autoimmune and inflammatory disorders based on its corporate identity, but no specific disease indications are named in the provided excerpts.

Value-chain role

Equillium is a drug developer without internal manufacturing. It relies on third-party contract manufacturers, clinical research organizations, and data management providers for nonclinical research, clinical studies, biostatistics, and safety reporting. It occupies an early-stage research and development role in the pharmaceutical value chain.

Geographic exposure

Principal offices are in La Jolla, California. The company has an Australian subsidiary, Equillium Australia Pty LTD, indicating some operational presence outside the United States. The filing references compliance obligations in the EEA and UK for data transfer, suggesting international clinical or research activity.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations Peers: Bolt Biotherapeutics Inc Cardiff Oncology Inc Cyteir Therapeutics, Inc. Korro Bio Inc Genprex Inc Synlogic Inc Passage Bio Inc TCR2 THERAPEUTICS INC. SQZ Biotechnologies Co